They said they expect to file the report before June 3 (or before they have to submit the plan to get current on filings). Hopefully they can get it done soon.
Very cool idea and good writeup. Couple quick thoughts- 1) Sorry if I'm stating the obvious, but it's a very elegant catalyst because the actual cost of MAPS product to its customers goes down since it becomes tax deductible post downscheduling. 2) Practically speaking you are right that the legal risk is zero but theoretically they are probably aiding and abetting. I have zero concern about an actual headline or event risk, but this might make it uninvestible for some institutional investors.
I probably won't buy it but I think the writeup is very well done.
I do agree, the fact that advertising becomes cheaper will certainly make the value prop more compelling, and I think would likely make dispensaries want to increase their spending.
Interesting point, which I did not really consider. As far as pushback on this idea, a few have commented to me that they like the idea but won't/can't invest because it's cannabis. So this will certainly not be for everybody.
It's sort of a moot point, since they stopped reporting MAU figures in 2022. And the lawsuit was settled for $1.5m... so now, I think it should no longer be an issue going forward.
What's your thoughts on this: WM Technology, Inc. Announces Notification of Delinquency with Nasdaq
https://ir.weedmaps.com/news-releases/news-release-details/wm-technology-inc-announces-notification-delinquency-nasdaq-0
They said they expect to file the report before June 3 (or before they have to submit the plan to get current on filings). Hopefully they can get it done soon.
Very cool idea and good writeup. Couple quick thoughts- 1) Sorry if I'm stating the obvious, but it's a very elegant catalyst because the actual cost of MAPS product to its customers goes down since it becomes tax deductible post downscheduling. 2) Practically speaking you are right that the legal risk is zero but theoretically they are probably aiding and abetting. I have zero concern about an actual headline or event risk, but this might make it uninvestible for some institutional investors.
I probably won't buy it but I think the writeup is very well done.
Also how did these people not choose the ticker WEED? They are so bad at memeing.
Thanks, Cliffs! Appreciate the kind words.
I do agree, the fact that advertising becomes cheaper will certainly make the value prop more compelling, and I think would likely make dispensaries want to increase their spending.
Interesting point, which I did not really consider. As far as pushback on this idea, a few have commented to me that they like the idea but won't/can't invest because it's cannabis. So this will certainly not be for everybody.
MAU’s. Do you think there is merit to it?
It's sort of a moot point, since they stopped reporting MAU figures in 2022. And the lawsuit was settled for $1.5m... so now, I think it should no longer be an issue going forward.
What’s going on with the recent lawsuit?
The one regarding MAUs? Or which one are you referring to?
What’s doing with maps weakness, should they have reported